Voyager Therapeutics Missed Consensus Estimates

Voyager Therapeutics (VYGR) reported a loss of $0.53 per share on revenue of $6.47 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.35 per share on revenue of $18.69 million. The company missed consensus estimates by 51.43% while revenue fell 66.83% compared to the same quarter a year ago.

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.